Kathryn Kennedy, MD
Gynecologic Oncology · Lincoln, NENPI 1932562725
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,160 of the $3,489 with a category attached, or 61.9%. Pfizer accounts for 62.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $2,203 and has fallen 86.2% since, to $305 in 2025.
Across 18 payments — averaging $193.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Medical Device Business Services, Inc.$683
- Octapharma USA, Inc.$240
- Davol Inc.$148
- GSK$96
- Intuitive Surgical$43
- plus $100 from 6 others
What the payments were for
- Consulting fees$2,16062%
- Travel & lodging$52115%
- Food & beverage$80823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $2,178 |
| Medical Device Business Services, Inc. | 6 | $683 |
| Octapharma USA, Inc. | 1 | $240 |
| Davol Inc. | 1 | $148 |
| GSK | 1 | $96 |
| Intuitive Surgical | 1 | $43 |
| Johnson & Johnson | 1 | $21 |
| Gilead | 1 | $17 |
| Merck | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$2,160
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$240
- ARISTA AH FLEXITIP$148
How this compares
Too few gynecologic oncology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 13 | $313 |
| Oxycodone Hcl | 30 | $106 |
| Fluconazole | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Lincoln
- Peter MorrisLincoln$2K
- David CrotzerOmaha$70K
- Steven RemmengaOmaha$4K
- Niyati NadkarniOmaha$2K
- Brent TierneyOmaha$1K
- Kerry RodabaughOmaha$411
- Robin Farias-EisnerOmaha$52
- Murray CaseyOmaha$37
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.